Subtopic Deep Dive
BCR-ABL Kinase Domain Mutations
Research Guide
What is BCR-ABL Kinase Domain Mutations?
BCR-ABL kinase domain mutations are point mutations in the BCR-ABL tyrosine kinase gene that confer resistance to tyrosine kinase inhibitors like imatinib in chronic myeloid leukemia patients.
These mutations, such as T315I, emerge under TKI selective pressure and reduce drug binding affinity. O’Hare et al. (2005) tested AMN107 (nilotinib) and BMS-354825 (dasatinib) against 15 clinically relevant imatinib-resistant Abl kinase domain mutants in vitro (1029 citations). Talpaz et al. (2006) showed dasatinib induces responses in imatinib-resistant CML patients harboring BCR-ABL mutations (1757 citations).
Why It Matters
BCR-ABL kinase domain mutations cause treatment failure in up to 20-30% of CML patients on first-line imatinib, necessitating switch to second-generation TKIs. Kantarjian et al. (2006) demonstrated nilotinib activity in imatinib-resistant CML with kinase mutations (1339 citations), while Cortes et al. (2013) reported ponatinib efficacy across mutation statuses including T315I (1108 citations). These insights guide mutation-specific therapies, improving progression-free survival. Hochhaus et al. (2020) recommend mutation testing for TKI selection in European LeukemiaNet guidelines (1444 citations).
Key Research Challenges
Detecting low-frequency mutations
Standard Sanger sequencing misses subclonal mutations below 20% variant allele frequency, delaying resistance prediction. Next-generation sequencing improves sensitivity but lacks standardization. O’Hare et al. (2005) identified 15 relevant mutants missed by early methods.
Overcoming T315I gatekeeper mutation
T315I sterically hinders TKI binding, resisting imatinib, dasatinib, and nilotinib. Ponatinib binds despite T315I but causes vascular events. Cortes et al. (2013) showed ponatinib activity against T315I in phase 2 trials.
Predicting compound mutations
Sequential TKIs select compound mutations like T315I/Y253H, reducing all current TKI efficacy. No validated models predict emergence from clonal dynamics. Pao et al. (2005) demonstrated secondary mutations drive acquired resistance in analogous EGFR setting.
Essential Papers
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao, Vincent A. Miller, Katerina Politi et al. · 2005 · PLoS Medicine · 3.5K citations
In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug. This observation should ...
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · 2006 · New England Journal of Medicine · 1.8K citations
Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTr...
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus, Michele Baccarani, Richard T. Silver et al. · 2020 · Leukemia · 1.4K citations
Tyrosine Kinases as Targets for Cancer Therapy
Daniela S. Krause, Richard A. Van Etten · 2005 · New England Journal of Medicine · 1.4K citations
Tyrosine kinases, enzymes that catalyze the transfer of phosphate from ATP to tyrosine residues in polypeptides, are ubiquitous, numerous, and of considerable clinical interest because they partici...
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle et al. · 2006 · New England Journal of Medicine · 1.3K citations
Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML. (ClinicalTrials.gov number, NCT00109707 [ClinicalTrials.gov].).
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · 2013 · New England Journal of Medicine · 1.1K citations
Ponatinib had significant antileukemic activity across categories of disease stage and mutation status. (Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov number, NCT01207440 .).
<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · 2005 · Cancer Research · 1.0K citations
Abstract Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients,...
Reading Guide
Foundational Papers
Start with O’Hare et al. (2005) for in vitro mutant profiling, Talpaz et al. (2006) for dasatinib clinical validation, and Kantarjian et al. (2006) for nilotinib responses—these establish mutation-TKI mismatch mechanisms.
Recent Advances
Study Hochhaus et al. (2020) for current testing/treatment guidelines and Cortes et al. (2013) for ponatinib's mutation-agnostic activity as key advances.
Core Methods
In vitro kinase assays (O’Hare 2005); phase 2 trials with mutation subanalysis (Talpaz 2006, Cortes 2013); NGS-based detection (Hochhaus 2020 guidelines).
How PapersFlow Helps You Research BCR-ABL Kinase Domain Mutations
Discover & Search
Research Agent uses searchPapers('BCR-ABL T315I mutation resistance') to retrieve O’Hare et al. (2005), then citationGraph reveals Talpaz et al. (2006) and Kantarjian et al. (2006) as downstream trials, while findSimilarPapers on Cortes et al. (2013) uncovers ponatinib alternatives, and exaSearch scans preprints for emerging allosteric inhibitors.
Analyze & Verify
Analysis Agent applies readPaperContent on O’Hare et al. (2005) to extract IC50 values for 15 mutants, verifies mutation spectra with verifyResponse (CoVe) against Hochhaus et al. (2020) guidelines, and runs PythonAnalysis to plot dasatinib vs nilotinib sensitivity curves using NumPy/pandas on trial data, with GRADE grading for evidence quality on T315I prevalence.
Synthesize & Write
Synthesis Agent detects gaps like 'compound mutation prevalence post-ponatinib' via contradiction flagging across Cortes (2013) and Hochhaus (2020), then Writing Agent uses latexEditText for mutation table revisions, latexSyncCitations to link 10 key papers, latexCompile for review-ready manuscript, and exportMermaid for kinase inhibitor resistance pathway diagrams.
Use Cases
"Extract and plot IC50 data for TKIs against BCR-ABL T315I from O’Hare 2005"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib plots IC50 bar chart with error bars) → researcher gets publication-ready figure exported as SVG.
"Draft review section on TKI sequencing for T315I-positive CML with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText (draft text) → latexSyncCitations (adds Talpaz 2006, Cortes 2013) → latexCompile → researcher gets compiled LaTeX PDF with auto-formatted references.
"Find open-source NGS pipelines for BCR-ABL mutation detection from papers"
Research Agent → searchPapers('BCR-ABL NGS detection') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets 3 vetted GitHub repos with mutation caller code, READMEs, and benchmark stats.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ CML mutation papers) → citationGraph clustering by TKI era → GRADE-scored summary report on mutation frequencies. DeepScan applies 7-step analysis with CoVe checkpoints: readPaperContent(Talpaz 2006) → extract mutation data → PythonAnalysis(statistical modeling) → verify against Hochhaus 2020. Theorizer generates hypotheses like 'allosteric inhibitors for compound mutants' from O’Hare (2005) + recent kinase evolution papers.
Frequently Asked Questions
What defines BCR-ABL kinase domain mutations?
Point mutations in BCR-ABL exons 4-9 (e.g., T315I, M351T) that alter ATP-binding or activation loop, reducing TKI affinity. O’Hare et al. (2005) cataloged 15 clinically relevant mutants from resistant CML patients.
What methods detect these mutations?
Sanger sequencing for >20% variants; NGS for ultrasensitive detection. Hochhaus et al. (2020) recommend mutation analysis at TKI failure using allele-specific PCR or NGS panels.
What are key papers on TKI resistance?
O’Hare et al. (2005) tested nilotinib/dasatinib in vitro (1029 citations); Talpaz et al. (2006) dasatinib phase 2 trial (1757 citations); Cortes et al. (2013) ponatinib across mutations (1108 citations).
What open problems remain?
Predicting compound mutation risk; T315I alternatives post-ponatinib toxicity; clonal evolution modeling. No TKIs fully evade all mutants per current literature.
Research Chronic Myeloid Leukemia Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching BCR-ABL Kinase Domain Mutations with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers